North Korea on May 21 reported more than 200,000 new patients suffering from fever for a fifth consecutive day, as the country fought its first confirmed coronavirus outbreak.
If you are not happy with the results below please do another search
50 search results for:
AbbVie submitted a New Drug Application to the U.S. Food and Drug Administration for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.
Infection with adenovirus, a common childhood virus, is the leading hypothesis for recent cases of severe hepatitis of unknown origin in children that have led to at least six deaths, U.S. health officials said on May 20.
The U.S. Food and Drug Administration approved Sanofi’s Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg. With this approval, Dupixent is the first and only medicine specifically indicated to treat EoE in the United States.
The World Health Organization was due to hold an emergency meeting on May 20 to discuss the recent outbreak of monkeypox, a viral infection more common to west and central Africa, after more than 100 cases were confirmed or suspected in Europe.
The World Health Organization’s European chief said on May 20 he is concerned that the spread of monkeypox could accelerate in the region as people gather for parties and festivals over the summer months.
Bayer terminated a two-year-old partnership with Atara Biotherapeutics that included the development of off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
Rice University researchers in Houston used the foundation of CRISPR/Cas9 technology to develop “drive-and-process” arrays, or DAP for short. The name may be simple, but the technology is complex and could be as groundbreaking as its predecessor. DAP is a mechanism that enables the editing of multiple DNA sites – rather than one at a time – to comprehensively reverse polygenic diseases resulting from multiple genetic predispositions.
The U.S. Food and Drug Administration issued a partial clinical hold for Foghorn Therapeutics’ Phase I clinical study, investigating the safety and efficacy of FHD-286 in patients with relapsed and/or refractory acute myelodysplastic leukemia (AML) and myelodysplastic syndromes (MDS). The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.
Aptamil maker Danone SA stepped up shipments of infant formula from Europe to address a shortage in the United States, according to U.S customs data and an analysis of ocean cargo data by shipping consultancy Ocean Audit for Reuters.